Uncategorized
Valeant Q1 financial report includes Siliq, Bausch + Lomb news
Valeant Pharmaceuticals International announced first quarter financial results, including a reduction of debt of $1.3 billion in the first quarter of 2017 and reduced total debt by $3.6 billion since the same period in 2016.The company’s total revenues were $2.109 billion, an 11% decrease from the first quarter of 2016, according to a news release from Valeant.